Drug Trial Radar · NCT04662255
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Apr 8, 2021
Primary completion
Nov 2027
Study completion Jun 2030
Sponsor
- Lead sponsor
- Loxo Oncology, Inc.Eli Lilly (LLY)
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Dec 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-305) to other drugs that work in a similar way that have already been approved by the United States Food and Drug Administration (US FDA). Participation could last up to two years, and possibly longer, if the disease does not progress.
Conditions
- Lymphoma, Mantle-Cell
Interventions
PirtobrutinibDrug
Oral
IbrutinibDrug
Oral
AcalabrutinibDrug
Oral
ZanubrutinibDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- To compare progression-free survival (PFS) of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL)Time frame: Up to approximately 24 months
Locations
189 sites in 24 countries. Site status is shown where the registry gives one.
Alaska Oncology and Hematology, LLC
Anchorage, Alaska
Arizona Oncology Associates, P.C. - HOPE
Phoenix, Arizona
UCLA Medical Center
Los Angeles, California
USO-Rocky Mountain Cancer Center
Denver, Colorado
Mayo Clinic in Florida
Jacksonville, Florida
Oncology-Hematology Associates of West Broward
Tamarac, Florida
Florida Cancer Specialists East
West Palm Beach, Florida
University of Kentucky Markey Cancer Center
Lexington, Kentucky
Mercy Health-Paducah Medical Oncology and Hematology
Paducah, Kentucky
Tulane Cancer Center Office of Clinical Research
New Orleans, Louisiana
Greenebaum Comprehensive Cancer Center
Baltimore, Maryland
DFCI Lymphoma
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Mayo Clinic
Rochester, Minnesota
Washington University Medical School
St Louis, Missouri
Columbia University Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Messino Cancer Center
Asheville, North Carolina
Levine Cancer Institute
Charlotte, North Carolina
Wake Forest University School of Medicine
Winston-Salem, North Carolina
Oncology Hematology Care Inc
Cincinnati, Ohio
Willamette Valley Cancer Institute & Research Ctr.
Eugene, Oregon
Sarah Cannon Research Institute SCRI
Nashville, Tennessee
Texas Oncology-Austin Midtown
Austin, Texas
Texas Oncology - Bedford
Bedford, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
Texas Oncology - McAllen
McAllen, Texas
Texas Oncology - Sherman
Sherman, Texas
US Oncology
The Woodlands, Texas
Texas Oncology - Tyler
Tyler, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
University of Virginia Health System
Charlottesville, Virginia
USO-Virginia Cancer Specialists, PC
Fairfax, Virginia
Seattle Cancer Care Alliance
Seattle, Washington
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
Froedtert Memorial Lutheran Hospital
Milwaukee, Wisconsin
Icon Cancer Care - The Wesley Medical Centre
Auchenflower, Australia
The St. George Hospital
Kogarah, New South Wales, Australia
Royal Hobart Hospital
Hobart, Tasmania, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
Showing 40 of 189 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.